Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System

Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System

Background: Automated insulin delivery systems are associated with improved glycemic outcomes for patients with diabetes. Ultrarapid lispro (URLi), which has an accelerated pharmacokinetic profile and shows superior postprandial glucose control compared to lispro (Humalog®), is a potential candidate...

Full description

Bibliographic Details
Main Authors: Bergenstal, R. (Author), Bode, B. (Author), Boyd, J. (Author), Carlson, A. (Author), Hardy, T. (Author), Ignaut, D. (Author), Liu, R. (Author), Morrett, S. (Author)
Format: Article
Language:English
Published: Mary Ann Liebert Inc. 2021
Subjects:
adult
Adult
antidiabetic agent
Article
Blood Glucose
blood glucose monitoring
clinical article
controlled study
crossover procedure
Cross-Over Studies
Diabetes Mellitus, Type 1
double blind procedure
drug safety
female
glucose
glucose blood level
glycemic control
hemoglobin A1c
human
Humans
Hybrid closed-loop
hyperglycemia
hypoglycemia
Hypoglycemic Agents
incidence
injection site erythema
injection site pain
injection site reaction
injection site swelling
insulin
Insulin
insulin aspart
insulin dependent diabetes mellitus
insulin infusion
Insulin Infusion Systems
insulin lispro
Insulin Lispro
insulin sensitivity
male
middle aged
randomized controlled trial
skin redness
Time in range
time to treatment
Ultrarapid lispro
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items